NAMS (NewAmsterdam Pharma) Short-Term Debt to Capital

Corporate company logo of NewAmsterdam Pharma (NAMS)

The NewAmsterdam Pharma (NAMS) price chart demonstrates the dynamics of a company relying on a lean staff of lipidologists and clinical trial specialists whose work is supported by European grants. The business is advancing metabolic medicine through partnerships with global centers, creating potential for acquisition by industry behemoths. The indicator stands at 0.00, while a strong personnel roster in cardiometabolic research and the targeted hiring of regulatory experts eliminate staff turnover.

Ratio of Short-Term Indebtedness to Capital: NewAmsterdam Pharma N.V. (NAMS) for 06/21/2023 - 11/01/2026

Analytical breakdowns for NewAmsterdam Pharma

- stock quotes and analyst forecast:
Stock Price NewAmsterdam Pharma N.V.|NAMS - Fair Value Consensus
- business market valuation indicators:
Market Capitalization NewAmsterdam Pharma Company|NAMS - Enterprise Value
- book capitalization information:
Net Assets per Single Share NewAmsterdam Pharma|NAMS - Accounting Value of Company|Market Value to Book Value Ratio newamsterdampharma.com|NAMS - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital NewAmsterdam Pharma|NAMS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio NewAmsterdam Pharma Company N.V.|NAMS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio NewAmsterdam Pharma Company|NAMS - Company Long-Term Liabilities|Company Short-Term Debts NewAmsterdam Pharma|Quick Liquidity Indicator newamsterdampharma.com
- company profitability and valuation multiples indicators:
NAMS - Profit After Payment of Taxes
Fundamental valuation:NAMS NewAmsterdam Pharma N.V.
Brand item of NewAmsterdam Pharma Company

This indicator measures the ratio of short-term liabilities to equity, determining the company's reliance on short-term borrowing to maintain liquidity. By analyzing the change in debt under one year relative to equity, an investor can assess the financial stability of NewAmsterdam Pharma (NAMS) in the face of massive expenditures required to launch innovative lipid-lowering drugs into a global market with colossal demand potential.

Competitors of NewAmsterdam Pharma

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|SLNO (Soleno Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|LUMO: Short-Term Debt to Capital Ratio|Organovo - Short-Term Debt to Capital|Current Liabilities to Capital Radius Recycling Inc.